UBE2S promotes malignant properties via VHL / HIF ‐1α and VHL / JAK2 / STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma
Cancer Medicine · 2023-09 · 12 (17) · 18078-18097
DOI: 10.1002/cam4.6431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.08.2023. Verfasst von Junyi Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jinan Microecological Biomedicine Shandong Laboratory, Shounuo City Light West Block, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Ubiquitin‐conjugating enzyme E2S (UBE2S), an E2 enzyme, is associated with the development of various tumors and exerts oncogenic activities. UBE2S is overexpressed in tumors, including hepatocellular carcinoma (HCC). However, the key molecular mechanisms of UBE2S in HCC still need additional research. The aim of this study was to explore the role of UBE2S in HCC.
Methods
The expression levels of UBE2S in HCC tissues and cells were detected by western blot analysis, quantitative real‐time polymerase chain reaction analysis (qRT–PCR), and immunohistochemistry (IHC). A 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H‐tetrazolium bromide (MTT) assay, wound healing assay, colony formation assay transwell assay, and animal models were used to detect the proliferation and migration ability of HCC cells. Western blot analysis, qRT–PCR, immunofluorescence, small‐interfering RNA (siRNA), and plasmid transfection and coimmunoprecipitation (Co‐IP) assays were performed to detect the interaction among UBE2S, von Hippel–Lindau (VHL), hypoxia‐inducible factor 1‐alpha (HIF‐1α), Janus kinase‐2 (JAK2), and signal transducer and activator of transcription 3 (STAT3).
Results
In this study, we found that high UBE2S expression was associated with poor prognosis in HCC patients. In addition, UBE2S expression was upregulated in HCC tissues and cell lines. Knockdown of UBE2S inhibited the proliferation and migration of HCC cells in vitro and in vivo by directly interacting with VHL to downregulate the HIF‐1α and JAK2/STAT3 signaling pathways. Accordingly, overexpression of UBE2S significantly enhanced the proliferation and migration of HCC cells in vitro via VHL to upregulate HIF‐1α and JAK2/STAT3 signaling pathways. Furthermore, we found that downregulation of UBE2S expression enhanced the sensitivity of HCC cells to sorafenib in vivo and in vitro.
Conclusion
UBE2S enhances malignant properties via the VHL/HIF‐1α and VHL/JAK2/STAT3 signaling pathways and reduces sensitivity to sorafenib in HCC. The findings of this study may open a new approach for HCC diagnosis and provide a potential option for the treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jinan Microecological Biomedicine Shandong Laboratory, Shounuo City Light West Block, Jinan, Shandong, China.
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
- Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Clinical Medicine and Rehabilitation, Jiangsu College of Nursing, Huai'an, Jiangsu, China.
- State Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing Univ…
ORCID-Profile: Junhua Wu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, J., Xu, X., Wu, S., Shi, W., Zhang, G., Cao, Y., Wang, Z., Wu, J., & Jiang, C. (2023). UBE2S promotes malignant properties via VHL / HIF ‐1α and VHL / JAK2 / STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma. Cancer Medicine, 12(17), 18078-18097. https://doi.org/10.1002/cam4.6431
Vancouver
Wu J, Xu X, Wu S, Shi W, Zhang G, Cao Y, et al. UBE2S promotes malignant properties via VHL / HIF ‐1α and VHL / JAK2 / STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma. Cancer Medicine. 2023;12(17):18078-18097. doi:10.1002/cam4.6431
BibTeX
@article{Wu2023,
author = {Wu, Junyi and Xu, Xiangjie and Wu, Shasha and Shi, Weiwei and Zhang, Guang and Cao, Yin and Wang, Zhongxia and Wu, Junhua and Jiang, Chunping},
title = {UBE2S promotes malignant properties via VHL / HIF ‐1α and VHL / JAK2 / STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {17},
pages = {18078--18097},
doi = {10.1002/cam4.6431}
}
EUVIMED